GSK pays $50M for 2 solid tumor cell therapies from Immatics

GSK pays $50M for 2 solid tumor cell therapies from Immatics

Source: 
Pharmaceutical Business Review
snippet: 

GlaxoSmithKline has struck a deal to access two Immatics T-cell receptor (TCR) therapeutics. The deal will see GSK pay $50 million (€46 million) upfront and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics.